NASDAQ
Total Transactions
7
5 buys /2 sells
Shares Acquired
417,678
Transactions: 5•Avg: 83,535.6
Shares Disposed
200,000
Transactions: 2•Avg: 100,000
Net Activity
+217,678
Net Buying•Ratio: 250%
Q4 2025(Current) | 417,678 | 200,000 | +217,678 | 250.00% |
Q3 2025 | 1,862,731 | 265,631 | +1,597,100 | 157.14% |
Q2 2025 | 1,215,771 | 57,619 | +1,158,152 | 141.67% |
Q1 2025 | 244,051 | 108,102 | +135,949 | 62.50% |
Q4 2024 | 199,709 | 329,418 | -129,709 | 50.00% |
This table shows insider trading activity by quarter. A ratio > 100% indicates insiders acquired more shares than they disposed of during the period, which is generally considered a bullish signal.
• Most recent data for Q4 2025
Acquired vs Disposed Shares
Net Accumulation: 217,678 shares•Acquired/Disposed Ratio: 250%
Net Activity | |||||
|---|---|---|---|---|---|
KK KOCH KEVIN | Director, officer: president and ceo | 17 | 650,521 | 59,905 | +590,616 |
TPA Thompson Peter A. | Director, 10 percent owner: | 3 | 526,771 | 0 | +526,771 |
OAL ORBIMED ADVISORS LLC | Director, 10 percent owner: | 2 | 496,771 | 0 | +496,771 |
NM Nofi Michael | Officer: chief financial officer | 3 | 306,250 | 0 | +306,250 |
BR Blaustein Robert | Officer: chief development officer | 3 | 282,500 | 0 | +282,500 |
This table shows the trading activity of the most active company insiders. Positive net activity (buying more than selling) is often considered a bullish signal.
2025-11-19 | Director | Purchase | 45,150 | $22.34 | $1,008,651 | 45,150 | |
2025-11-19 | Unknown | Sale | 0 | $0 | $0 | - | |
2025-11-12 | Director, officer: chief scientific officer | Sale | 100,000 | $0.18 | $18,000 | 1,147,365 | |
2025-11-12 | Director, officer: chief scientific officer | Purchase | 100,000 | $0.18 | $18,000 | 123,400 | |
2025-11-12 | Director, officer: chief scientific officer | Sale | 100,000 | $21.12 | $2,112,450 | 23,400 |
This table displays recent Form 4 filings showing transactions by company insiders. SEC rules require insiders to report their transactions within two business days.
MCN Martin Christopher Nathan | Director | Nov 24, 2025 | |
MCN Martin Christopher Nathan | Unknown | Nov 24, 2025 | |
RAJ Russell Alan J | Director, officer: chief scientific officer | Nov 13, 2025 | |
RAJ Russell Alan J | Director, officer: chief scientific officer | Nov 13, 2025 | |
RAJ Russell Alan J | Director, officer: chief scientific officer | Nov 13, 2025 |
Net change in shares shown on right
No price data available for this timeframe.